GlaxoSmithKline Pharmaceuticals Limited has notified the stock exchanges regarding the upload of analyst and institutional investor meeting recordings on its official website. The company has communicated this development to both BSE Limited and the National Stock Exchange of India Limited through an official letter dated 6th November 2025.

Regulatory Compliance

The pharmaceutical company has fulfilled its disclosure obligations pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to disclose material events and information that could impact investor decisions.

Recording Availability

The audio recording of the analyst and institutional investor meetings has been uploaded to the company's dedicated investor portal. Stakeholders can access the recording through the company's official website at india-pharma.gsk.com under the investors section.

Corporate Information

The notification was signed by Ajay Nadkarni, who serves as Vice President – Administration, Real Estate & Company Secretary for GlaxoSmithKline Pharmaceuticals Limited. The company is headquartered at GSK House, Dr. Annie Besant Road, Worli, Mumbai, and operates under CIN: L24239MH1924PLC001151.

This disclosure ensures transparency and provides investors with access to important corporate communications and strategic discussions held during the analyst meetings.

GlaxoSmithKline Pharmaceuticals Limited has informed stock exchanges about receiving a GST demand order from Maharashtra State GST authorities. The pharmaceutical company disclosed this development under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

GST Demand Order Details

The company received an order dated December 31, 2025, from the Assistant Commissioner of State Tax, Mumbai, Maharashtra, pertaining to FY 2021-22. The comprehensive breakdown of the demand order is presented below:

Nature of Violation

The GST authorities have raised the demand in relation to GST credit-related issues. Specifically, the order addresses mismatches between the company's GST returns and the details reported by its suppliers. This type of discrepancy is a common area of scrutiny by tax authorities during GST assessments.

Company's Response and Impact Assessment

GlaxoSmithKline Pharmaceuticals has clarified that the demand order will have no impact on the company's financial operations. The management is currently evaluating the demand order and has indicated that it will take appropriate actions in due course. This suggests the company may consider filing an appeal or providing additional documentation to address the authorities' concerns.

Regulatory Compliance

The disclosure was made on January 1, 2026, following the company's receipt of the order on December 31, 2025. This timely disclosure demonstrates the company's commitment to maintaining transparency with stakeholders and adhering to regulatory requirements under SEBI guidelines.

The company's proactive approach to addressing the GST demand order reflects its commitment to resolving tax-related matters while ensuring minimal disruption to its business operations.